406 related articles for article (PubMed ID: 21720501)
1. Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents.
Dinarvand R; Sepehri N; Manoochehri S; Rouhani H; Atyabi F
Int J Nanomedicine; 2011; 6():877-95. PubMed ID: 21720501
[TBL] [Abstract][Full Text] [Related]
2. PLGA Nanoparticles and Their Versatile Role in Anticancer Drug Delivery.
Khan I; Gothwal A; Sharma AK; Kesharwani P; Gupta L; Iyer AK; Gupta U
Crit Rev Ther Drug Carrier Syst; 2016; 33(2):159-93. PubMed ID: 27651101
[TBL] [Abstract][Full Text] [Related]
3. PLGA-based nanoparticles as cancer drug delivery systems.
Sadat Tabatabaei Mirakabad F; Nejati-Koshki K; Akbarzadeh A; Yamchi MR; Milani M; Zarghami N; Zeighamian V; Rahimzadeh A; Alimohammadi S; Hanifehpour Y; Joo SW
Asian Pac J Cancer Prev; 2014; 15(2):517-35. PubMed ID: 24568455
[TBL] [Abstract][Full Text] [Related]
4. Hyaluronic acid-grafted PLGA nanoparticles for the sustained delivery of berberine chloride for an efficient suppression of Ehrlich ascites tumors.
Bhatnagar P; Kumari M; Pahuja R; Pant AB; Shukla Y; Kumar P; Gupta KC
Drug Deliv Transl Res; 2018 Jun; 8(3):565-579. PubMed ID: 29441466
[TBL] [Abstract][Full Text] [Related]
5. Preparation of polylactide-co-glycolide nanoparticles incorporating celecoxib and their antitumor activity against brain tumor cells.
Kim TH; Jeong YI; Jin SG; Pei J; Jung TY; Moon KS; Kim IY; Kang SS; Jung S
Int J Nanomedicine; 2011; 6():2621-31. PubMed ID: 22114493
[TBL] [Abstract][Full Text] [Related]
6. Poly(D,L-lactide-co-glycolide) nanoparticles encapsulated fluorescent isothiocyanate and paclitaxol: preparation, release kinetics and anticancer effect.
Yang H; Li K; Liu Y; Liu Z; Miyoshi H
J Nanosci Nanotechnol; 2009 Jan; 9(1):282-7. PubMed ID: 19441308
[TBL] [Abstract][Full Text] [Related]
7. Biodegradable nanoparticles for drug and gene delivery to cells and tissue.
Panyam J; Labhasetwar V
Adv Drug Deliv Rev; 2003 Feb; 55(3):329-47. PubMed ID: 12628320
[TBL] [Abstract][Full Text] [Related]
8. Engineered PLGA nanoparticles: an emerging delivery tool in cancer therapeutics.
Jain AK; Das M; Swarnakar NK; Jain S
Crit Rev Ther Drug Carrier Syst; 2011; 28(1):1-45. PubMed ID: 21395514
[TBL] [Abstract][Full Text] [Related]
9. Biodegradable nanoparticles containing doxorubicin-PLGA conjugate for sustained release.
Yoo HS; Oh JE; Lee KH; Park TG
Pharm Res; 1999 Jul; 16(7):1114-8. PubMed ID: 10450940
[TBL] [Abstract][Full Text] [Related]
10. Biological evaluation of 5-fluorouracil nanoparticles for cancer chemotherapy and its dependence on the carrier, PLGA.
Nair K L; Jagadeeshan S; Nair SA; Kumar GS
Int J Nanomedicine; 2011; 6():1685-97. PubMed ID: 21980233
[TBL] [Abstract][Full Text] [Related]
11. Concepts and practices used to develop functional PLGA-based nanoparticulate systems.
Sah H; Thoma LA; Desu HR; Sah E; Wood GC
Int J Nanomedicine; 2013; 8():747-65. PubMed ID: 23459088
[TBL] [Abstract][Full Text] [Related]
12. Preparation of DHAQ-loaded mPEG-PLGA-mPEG nanoparticles and evaluation of drug release behaviors in vitro/in vivo.
Duan Y; Sun X; Gong T; Wang Q; Zhang Z
J Mater Sci Mater Med; 2006 Jun; 17(6):509-16. PubMed ID: 16691348
[TBL] [Abstract][Full Text] [Related]
13. A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS.
Mu L; Feng SS
J Control Release; 2003 Jan; 86(1):33-48. PubMed ID: 12490371
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin-incorporated polymeric micelles composed of dextran-b-poly(DL-lactide-co-glycolide) copolymer.
Jeong YI; Kim DH; Chung CW; Yoo JJ; Choi KH; Kim CH; Ha SH; Kang DH
Int J Nanomedicine; 2011; 6():1415-27. PubMed ID: 21796244
[TBL] [Abstract][Full Text] [Related]
15. Possibilities of poly(D,L-lactide-co-glycolide) in the formulation of nanomedicines against cancer.
Holgado MA; Alvarez-Fuentes J; Fernández-Arévalo M; Arias JL
Curr Drug Targets; 2011 Jul; 12(8):1096-111. PubMed ID: 21443478
[TBL] [Abstract][Full Text] [Related]
16. Drug-loaded PLGA nanoparticles for oral administration: fundamental issues and challenges ahead.
Kumar G; Shafiq N; Malhotra S
Crit Rev Ther Drug Carrier Syst; 2012; 29(2):149-82. PubMed ID: 22475089
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity.
Fonseca C; Simões S; Gaspar R
J Control Release; 2002 Oct; 83(2):273-286. PubMed ID: 12363453
[TBL] [Abstract][Full Text] [Related]
18. Passively Targeted Curcumin-Loaded PEGylated PLGA Nanocapsules for Colon Cancer Therapy In Vivo.
Klippstein R; Wang JT; El-Gogary RI; Bai J; Mustafa F; Rubio N; Bansal S; Al-Jamal WT; Al-Jamal KT
Small; 2015 Sep; 11(36):4704-22. PubMed ID: 26140363
[TBL] [Abstract][Full Text] [Related]
19. Biocompatibility and biodistribution of suberoylanilide hydroxamic acid loaded poly (DL-lactide-co-glycolide) nanoparticles for targeted drug delivery in cancer.
Sankar R; Ravikumar V
Biomed Pharmacother; 2014 Sep; 68(7):865-71. PubMed ID: 25107842
[TBL] [Abstract][Full Text] [Related]
20. Formulation and evaluation of biodegradable nanoparticles for the oral delivery of fenretinide.
Graves RA; Ledet GA; Glotser EY; Mitchner DM; Bostanian LA; Mandal TK
Eur J Pharm Sci; 2015 Aug; 76():1-9. PubMed ID: 25933716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
